Roche shuffles early stage pipeline as it joins obesity rush
Bio Pharma Dive
FEBRUARY 1, 2024
Roche said it was shelving those drugs in favor of experimental programs to treat obesity that it gained from its takeover of Carmot Therapeutics.
Thu.Feb 01, 2024
310 
Keytruda remains Merck & Co’s biggest 2023 success story as patent expiry looms
Pharmaceutical Technology
FEBRUARY 1, 2024
Merck & Co (MSD) has reported a 1% revenue increase from 2022, and may face setbacks in the next few years from top-selling drugs.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Takeda pays $300M to license Protagonist drug for blood disorder
Bio Pharma Dive
FEBRUARY 1, 2024
The agreement gives Protagonist an experienced hand in Takeda, which can help the former commercialize its product.
Novartis reports 62% rise in FY 2023 net income
Pharmaceutical Technology
FEBRUARY 1, 2024
Novartis has announced net income soaring by 62% to $8.6bn for the full year 2023 (FY 2023) from the previous year’s $6.04bn.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Sanofi appoints Nestlé executive as new finance chief
Bio Pharma Dive
FEBRUARY 1, 2024
François-Xavier Roger will replace current CFO Jean-Baptiste Chasseloup de Chatillon as Sanofi continues a research pivot and cost-cutting drive.
Cancer treatment could identify patients most likely to respond to cancer drugs
Pharma Times
FEBRUARY 1, 2024
Tumours with high mtDNA mutations more likely to respond to Opdivo
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
NeoPhore adds $12.2m in Series B extension for immuno-oncology pipeline
Pharmaceutical Technology
FEBRUARY 1, 2024
The financing extension brings Series B total funding to $39.5m, helping advance the UK company’s lead DNA MMR protein candidate.
Millions of people to view digital prescriptions via the NHS app
Pharma Times
FEBRUARY 1, 2024
Prescriptions ordered via the app are expected to save around 1.
Vivet wins $5.3m grant to develop gene therapy for rare metabolic disorder
Pharmaceutical Technology
FEBRUARY 1, 2024
The French government grant will cover preclinical and clinical research for Vivet’s gene therapy for cerebrotendinous xanthomatosis.
Hybrid and multi-cloud: The next step for biotech to secure flexible, scalable scientific workflows
pharmaphorum
FEBRUARY 1, 2024
Hybrid and multi-cloud: The next step for biotech to secure flexible, scalable scientific workflows Mike.
Almirall and Microsoft partner for dermatological drug development
Pharmaceutical Technology
FEBRUARY 1, 2024
Almirall has entered a strategic collaboration with Microsoft to steer innovation and digital transformation in dermatology.
Merck still in the market for deals in the $1B to $15B range, CEO says
Fierce Pharma
FEBRUARY 1, 2024
Even after the acquisitions of Prometheus and Acceleron, Merck is ready to make more deals in the $1 to $15 billion range, according to CEO Rob Davis.
Excellence Awards Report 2023
Pharmaceutical Technology
FEBRUARY 1, 2024
Our Awards and Rankings report is available now to download
Who's No. 1? With $25B in sales, Merck's Keytruda looks to be the top-selling drug of 2023
Fierce Pharma
FEBRUARY 1, 2024
With Merck reporting a whopping $25 billion sales haul for | With Merck reporting a whopping $25 billion sales haul for Keytruda on Thursday, the PD-1 cancer superstar appears to be the world’s top-selling drug in 2023. Keytruda looks set to take over the top spot from Pfizer and BioNTech’s Comirnaty, which ruled the previous two years, scoring sales of $55.9 billion in 2022 and $55.1 billion in 2021.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
The new technologies helping biopharmaceutical trailblazers accelerate progress from research to market
Pharmaceutical Technology
FEBRUARY 1, 2024
Getting new drugs out of the research phase, and into clinical studies and commercialization, is an odyssey in quality control
Sanofi expects RSV antibody to ?breach blockbuster status in 2024, even as supply hitch drags on
Fierce Pharma
FEBRUARY 1, 2024
As Sanofi strives to become a global immunology leader, it's also busy making the most of a crucial respiratory launch with partner AstraZeneca. | As Sanofi strives to become a global immunology leader, it's also busy making the most of a crucial respiratory launch with partner AstraZeneca. On both fronts, Sanofi expects to see dividends in 2024.
Excellence Awards Report 2023
Pharmaceutical Technology
FEBRUARY 1, 2024
Our Awards and Rankings report is available now to download
Making connections and getting noticed as a biotech start-up
pharmaphorum
FEBRUARY 1, 2024
On today's podcast, brought to you by Kadans Science Partners, host Jonah Comstock is joined by Bradley Hardiman, Astellas Pharma’s Senior Director of Business Development; Mike Murray, head of Murray International Partners Ltd; and Mairi Dillon, Kadans' Ecosystem Manager for UK & Ireland.
Healthcare providers favour pricing control as US drug costs soar
Pharmaceutical Technology
FEBRUARY 1, 2024
GlobalData reports that HCPs predict a continued increase in drug prices, as inflationary pressures rise.
Healthcare sector cybersecurity retrospective and the year ahead
pharmaphorum
FEBRUARY 1, 2024
As cyberattacks continue to target the healthcare sector, it is crucial to look back at cybersecurity incidents from the past year and prepare for the challenges that lie ahead. This retrospective discusses the impact on patients, health systems, insurers, and vendors, and highlights the importance of cybersecurity measures in protecting sensitive healthcare information.
UK MHRA approves GSK’s momelotinib for myelofibrosis anaemia
Pharmaceutical Technology
FEBRUARY 1, 2024
The UK MHRA has approved the use of GSK’s momelotinib (Omjjara) for moderate to severe anaemia in adult patients with myelofibrosis.
GSK inks another Zantac settlement ahead of trial in California
Fierce Pharma
FEBRUARY 1, 2024
After GSK spent the latter half of 2023 warding off concerns about the swelling Zantac product liability litigation, the company is back at the settlement table in 2024. | After GSK spent the latter half of 2023 warding off concerns about the swelling Zantac product liability litigation, the company is back at the settlement table in 2024.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Takeda and Protagonist sign rusfertide development deal
Pharmaceutical Technology
FEBRUARY 1, 2024
Takeda has entered a global licence and partnership agreement with Protagonist Therapeutics for developing and marketing rusfertide.
In Medicare negotiation process, HHS sends 1st price offers as industry blasts lack of transparency
Fierce Pharma
FEBRUARY 1, 2024
Despite litigation and denouncements from the biopharma industry, Medicare price negotiations under the Inflation Reduction Act are rolling on. | Despite litigation and denouncements from the biopharma industry, Medicare price negotiations under the Inflation Reduction Act are rolling on. And today, the government is sending out its first round of offers on affected drugs.
In-person, hybrid, or digital? State of pharma meetings and events in 2024
pharmaphorum
FEBRUARY 1, 2024
Explore the current state of pharmaceutical meetings and events in 2024, including the shift from in-person to virtual and hybrid formats. Discover how the industry is embracing diversity, equity, and inclusion in these gatherings.
Despite Roche's sharp COVID sales decline, eye drug Vabysmo powers major revenue win, CEO says
Fierce Pharma
FEBRUARY 1, 2024
As Roche CEO Thomas Schinecker sees it, the Swiss pharma made a “major achievement” in 2023. Despite a sharp decline in COVID-related sales, the company was able to grow overall revenues | As Roche CEO Thomas Schinecker sees it, the Swiss pharma made a “major achievement” in 2023. Despite a sharp decline in COVID-related sales, the company was able to grow overall revenues thanks in large part to the performance of eye disease drug Vabysmo.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Almirall, Microsoft team up on digital dermatology drive
pharmaphorum
FEBRUARY 1, 2024
Almirall has formed a three-year alliance with Microsoft designed to accelerate the discovery and development of personalised dermatology therapies.
Despite Vyvanse’s loss of exclusivity, Takeda treads water thanks to launch momentum
Fierce Pharma
FEBRUARY 1, 2024
Despite the recent loss of exclusivity on Takeda's ADH | As Vyvanse generics take a chunk out of Takeda's sales, the company is hopeful its roster of new drugs, including its dengue fever vaccine Qdenga, can keep revenues intact.
Lundbeck study knocks confidence in alpha-syn as CNS target
pharmaphorum
FEBRUARY 1, 2024
A phase 2 trial of Lundbeck’s alpha-synuclein-targeting drug Lu AF82422 has failed to reach statistical significance in patients with multiple system atrophy (MSA), although the company says there are encouraging “signals of efficacy” in the data.
Beyond chemotherapy: Navigating the promise and perils of CAR-T therapy in pediatric cancer
BioPharma Reporter
FEBRUARY 1, 2024
Upon hearing the phrase âcancer treatmentâ, the first word that can typically spring to mind is chemotherapy â a primary therapy which uses powerful chemicals to destroy rapidly growing cancer cells in the body.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content